RET fusion positive cancer
MONDO:0700216Neoplasm associated with expression of a RET (REarranged during Transfection) fusion. RET fusion-positive tumors have been identified in a broad range of solid tumor types, including multiple endocrine neoplasia 2 (MEN2), papillary thyroid carcinoma (PTC), non-small cell lung cancer (NSCLC), invasive breast cancers, and pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.
Also known as: RET fusion positive neoplasm, RET fusion positive solid tumor, RET fusion positive solid tumour
1450 clinical trials for this condition and its sub-types, 20 tagged with RET fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New pill targets Hard-to-Treat cancers after other drugs fail
Disease control CompletedThis early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can sh…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC